#Canada #Toronto #Webinar #antibody-drug conjugates #Xtalks

Upcoming Webinar on Reducing ADC Conjugation Risks

Antibody-drug conjugates (ADCs) have emerged as a potent therapeutic strategy in oncology, combining the targeting capability of monoclonal antibodies with the cytotoxic power of drug payloads. However, the consistency and quality of these antibodies are paramount in ensuring successful conjugation and performance of ADCs. A forthcoming webinar hosted by Xtalks, scheduled for September 24, 2026, aims to delve deep into these pivotal issues affecting the ADC manufacturing process.

Key Topics to be Discussed

The webinar will feature discussions around several significant aspects of antibody production and their relevance in conjugation for ADCs. Attendees can expect to learn about:

1. Importance of Consistent Antibody Quality: Understand how maintaining specific quality attributes of antibodies during the entire development and manufacturing phase is critical. This aspect directly impacts the efficiency of the conjugation process and the performance of the resulting ADC.

2. Crucial Factors in ADC Manufacturing: Attendees will explore key parameters such as antigen specificity, binding strength, and structural stability, which play a vital role in the effectiveness of ADC therapies. Moreover, the session will touch on the readiness of antibodies for chemical conjugation.

3. Upstream Production Processes: Discussion on how cell line development and upstream production workflows influence the quantity and quality of antibody outputs will be highlighted. An in-depth look into the purification workflows that help minimize impurity presence prior to payload attachment will also be featured.

4. Scale-Up Considerations: As ADC projects transition from early development to clinical and commercial manufacturing, challenges related to reproducibility and quality control become more pronounced. The webinar aims to cover how maintaining stable antibody quality during scale-up can mitigate risks and enhance predictability in final ADC performance.

Real-World Insights and Success Stories

An insightful segment of the webinar will showcase a success story that demonstrates the impact of antibody glycosylation patterns on conjugation efficiency. This case study will illustrate how optimized upstream processes can enhance consistency across various antibody quality attributes, leading to improved manufacturing outcomes.

Expert Guidance for Development Teams

Attendees will benefit from insights on securing support from experienced Contract Development and Manufacturing Organizations (CDMOs) to streamline antibody production processes. Participants will gain exposure to strategies for addressing quality variability and progressing towards successful downstream conjugation and commercial readiness.

Register and Join the Discussion

This webinar is a must-attend event for professionals involved in the life sciences and pharmaceutical industries, especially those focused on ADC development. Interested participants are encouraged to register for the session with Dave Briggs, PhD, MSAT Principal Scientist at Avid Bioservices, who will share valuable methodologies and insights on ensuring quality in ADC manufacturing strategies.

By attending, you will acquire essential knowledge on how to maintain antibody consistency, enhance conjugation efficiency, and effectively manage scale-up risks for ADCs.

Do not miss this opportunity to gain insights from experts and enhance your knowledge in the field. To register for the event, visit the Xtalks website and secure your spot for this informative session.

About Xtalks

Xtalks is renowned for empowering life science professionals across various domains, including pharma, biotech, medtech, and research, with credible knowledge and insights. Their platform provides a wealth of resources, encompassing webinars, articles, and interviews to facilitate informed decision-making in an ever-evolving industry landscape. Join thousands of professionals reliant on Xtalks to remain updated and connected in this dynamic sector.